Cardiovascular disease and lipid management in New Zealand: Progress at last!

Abstract

Is summary, we are now experiencing a paradigm shift in our understanding of the role of lipid management and cardiovascular disease. There are currently approximately 120 000 New Zealanders receiving lipid-modifying agents. A figure closer to 400 000 within five years would vastly improve patient outcomes for cardiovascular disease, the commonest cause of death and major morbidity in New Zealand. The impending changes to access if coupled with utilisation of the soon to be available guidelines will allow most high-risk patients to be more effectively treated. All doctors have a responsibility to use this clinical resource efficiently and wisely.